Eylea Success Rate – Efficacy in Treating Retinal Diseases

Last Updated On: February 4, 2025

Age-related macular degeneration (AMD) is a leading cause of vision loss in the United States. According to the Vision and Eye Health Surveillance System (VEHSS), an estimated 19.8 million Americans aged 40 and older were living with AMD in 2019. As the population continues to age, projections indicate that the number of affected individuals could reach 35 million by 2050.

Eylea (aflibercept) is a widely used anti-vascular endothelial growth factor (anti-VEGF) therapy designed to treat AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). By inhibiting abnormal blood vessel growth and leakage, Eylea helps preserve vision and slow disease progression.

In this article, we will explore Eylea’s success rate, examining clinical trial results, real-world treatment outcomes, and its overall efficacy in managing retinal diseases.

Key Takeaways

• Eylea is a prominent treatment for retinal diseases such as wet AMD, DME, and RVO and primarily blocks VEGF to reduce retinal swelling and abnormal blood vessel growth.
• Clinical trials demonstrate high success rates, with 93-100% of wet AMD patients maintaining vision after one year. It helps patients achieve improved visual acuity after two years.
• Many patients report life-changing improvements in quality of life. This reduces Eylea’s representing to increased independence and daily activities.
• Success factors include early diagnosis, adherence to a treatment schedule, management of underlying health conditions, and individual responses to therapy.
• While Eylea helps stabilize vision and can improve it for some, complete restoration of lost vision is rare. Patients are encouraged to have realistic expectations regarding their treatment outcomes. 

About: ​​Med Supply Solutions has been operating since 2016 and is known as one of the industry’s top and trusted suppliers of cosmetic and viscosupplementation products. Contact our sales department for more information about buying Eylea online. 

Overview of Eylea’s Efficacy in Retinal Diseases

Eylea is a leading treatment for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It helps slow disease progression and, in some cases, can even improve vision. By blocking vascular endothelial growth factor (VEGF), Eylea prevents abnormal blood vessel growth, reduces retinal swelling, and protects against further vision loss.

Its effectiveness varies based on the condition being treated:

• Wet AMD: Helps prevent severe vision loss and may enhance visual acuity.
• DME: Reduces retinal swelling and helps stabilize vision.
• RVO: Controls fluid leakage in the retina, preventing further deterioration of vision.

When comparing anti-VEGF treatments like Eylea vs Lucentis, one key advantage of Eylea is its longer duration of action. It often requires fewer injections, making it a more convenient option for many patients.

Clinical Data and Real-World Outcomes

Several clinical trials and real-world studies have assessed Eylea’s effectiveness in treating retinal diseases, demonstrating high success rates in preserving and improving vision. Below are the key findings:

• Wet AMD: The VIEW 1 and VIEW 2 trials showed that 93-100% of patients maintained vision after one year of Eylea treatment, with some experiencing notable vision improvement.
• DME: The VISTA and VIVID studies reported that 41-58% of patients gained at least 15 letters in visual acuity after two years of treatment.
• RVO: Clinical studies indicate that many patients achieved significant visual improvement following regular Eylea injections.

Beyond clinical data, real-world patient feedback highlights the life-changing impact of Eylea’s treatment:

•  “I have been in clinical trials for four years with Eylea and have had no side effects. Eylea has allowed me to return to a quality of life I had given up—sewing, painting, cooking, driving, reading, and more. Before Eylea, I had even stopped watching TV! Now, I feel confident again and go out without fear. This has been a truly positive, life-changing experience.
•  “I have had wet macular degeneration for four years. So far, I’ve received 14 Eylea injections in my left eye. Initially, I had monthly injections, but now I only need one per year. Injection pain and redness varied depending on the injector’s experience, but all cleared up fine. At my last examination, no active signs of AMD were in my treated eye.”

In real-world clinical settings, Eylea demonstrates substantial long-term success. Many patients achieve disease stability and experience a reduced treatment burden compared to alternative therapies.

Factors Contributing to Eylea’s Success

Eylea is highly effective in treating retinal diseases, but several factors influence treatment success and long-term vision outcomes. Understanding these factors can help patients and healthcare providers optimize results.

• Early Diagnosis & Treatment: Starting Eylea treatment as early as possible increases the chances of preserving vision and preventing further retinal damage. Delayed treatment may lead to irreversible vision loss.
• Adherence to Treatment: Consistency is crucial. Missing scheduled injections can reduce Eylea’s effectiveness, leading to disease progression and poorer vision outcomes. Patients should strictly follow their ophthalmologist’s recommended schedule.
• Underlying Health Conditions: Diabetes, hypertension, and other systemic conditions can impact how well patients respond to anti-VEGF therapy. Properly managing these conditions can enhance treatment success and overall eye health.
• Individual Response to Anti-VEGF Therapy: Not all patients respond to Eylea in the same way. Some may require dose adjustments or a personalized treatment plan to achieve the best results. For non-responders, alternative therapies may be considered.
• Injection Frequency & Dosing Schedule: Sticking to the recommended treatment schedule ensures optimal drug effectiveness. While Eylea often requires fewer injections than other anti-VEGF treatments, maintaining a consistent dosing regimen is essential for long-term disease control.

Setting Patient Expectations

While Eylea has a high success rate, it’s important for patients to have realistic expectations about their treatment outcomes.

• Vision Stabilization vs. Restoration: Most patients experience vision stabilization, meaning Eylea helps prevent further decline rather than fully restoring lost vision. Some patients may regain a certain level of vision, but complete restoration is rare.
• Long-Term Commitment: Eylea requires ongoing treatment, with regular injections needed to maintain results and prevent disease progression.
• Potential Side Effects: Mild side effects like eye redness, irritation, or temporary discomfort are common but usually resolve quickly. Serious complications are rare but require immediate medical attention.

By understanding what to expect, patients can stay motivated and committed to their treatment, ensuring they receive the full benefits of Eylea’s vision-preserving effects.

Conclusion

Eylea is a highly effective anti-VEGF therapy, backed by strong clinical and real-world evidence in the treatment of wet AMD, DME, and RVO. Its ability to stabilize vision and, in many cases, improve visual acuity makes it a leading choice for retinal disease management.

While individual results may vary, early intervention, consistent treatment adherence, and patient education are essential for achieving the best possible outcomes. If you or a loved one is considering Eylea, consult with a retina specialist to determine the most effective treatment plan for your condition.

FAQs

1. What is the Eylea success rate for wet AMD?

Clinical trials have demonstrated that Eylea can help maintain or improve vision in many patients with wet AMD. In one study, 75% of patients either gained or did not lose vision through the second year of treatment. Additionally, Eylea has been shown to require fewer injections compared to some other treatments, which can be more convenient for patients.

2. How does Eylea compare to Lucentis?

Eylea and Lucentis are effective anti-VEGF treatments, but Eylea often requires fewer injections, making it a more convenient option for many patients.

3. How long does Eylea’s treatment last?

Eylea tEylea’sent is long-term and requires regular injections to maintain vision stability. The dosing schedule varies depending on the condition being treated.

4. What are the common side effects of Eylea?

Mild side effects include eye redness, discomfort, and temporary vision changes. Serious complications like infections or retinal detachment are rare but require immediate medical attention.

References

CDC. VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD). Vision and Eye Health Surveillance System. Published November 26, 2024. https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html‌

Sugue M. Age-related Macular Degeneration Statistics 2024 – Vision Center. Vision Center. Published May 29, 2024. https://www.visioncenter.org/resources/amd-prevention-statistics/